Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Document Type
Journal Article
Publication Date
11-1-2018
Journal
Obstetrics and Gynecology
Volume
132
Issue
5
Inclusive Pages
1252-1264
DOI
10.1097/AOG.0000000000002933
Keywords
Adult; Contraceptive Agents, Female; Double-Blind Method; Drug Therapy, Combination; Estradiol; Estrogens; Female; Gonadotropin-Releasing Hormone; Hemoglobins; Humans; Hydrocarbons, Fluorinated; Leiomyoma; Menorrhagia; Middle Aged; Norethindrone Acetate; Pyrimidines; Quality of Life; Tumor Burden; Uterine Neoplasms
APA Citation
Carr, B., Stewart, E., Archer, D., Al-Hendy, A., Bradley, L., Watts, N., Diamond, M., Gao, J., Owens, C., Chwalisz, K., Duan, W., Soliman, A., Dufek, M., & Simon, J. A. (2018). Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.. Obstetrics and Gynecology, 132 (5). http://dx.doi.org/10.1097/AOG.0000000000002933
